rocuronium and Sensation-Disorders

Significant progress in the management of aminosteroid nondepolarizing neuromuscular blockers will follow the introduction of sugammadex (Org 25969). Safety and rapid recovery of muscle force will improve and the adverse effects of acetylcholinesterase inhibitors will be avoided. Sugammadex is a modified gamma-cyclodextrin agent developed for the specific reversal of rocuronium and, to a lesser extent, vecuronium. This novel drug functions by means of encapsulation (chelation). Sugammadex was recently approved by the European Medicines Evaluation Agency and became available in Spain in 2009, leading to a series of changes related to patient safety and surgical conditions. We review the literature on sugammadex published to date.

Topics: Androstanols; Anesthesia Recovery Period; Chelating Agents; Clinical Trials as Topic; Drug Approval; Europe; gamma-Cyclodextrins; Humans; Neuromuscular Blockade; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents; Postoperative Complications; Receptors, Cholinergic; Rocuronium; Sensation Disorders; Sugammadex; Vecuronium Bromide; Vomiting